Latest Period
Q4 2025
Security Snapshot
Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) Institutional Ownership
CUSIP: 74065P101
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
48
Shares (Excl. Options)
28,472,272
Price
$2.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- PRLD on Nasdaq
- Shares outstanding
- 65,427,364
- Price per share
- $4.22
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 28,472,272
- Total reported value
- $82,563,685
- % of total 13F portfolios
- 0%
- Share change
- +1,310,394
- Value change
- +$4,105,718
- Number of holders
- 48
- Price from insider filings
- $4.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share is tracked under CUSIP 74065P101.
- 48 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 48 to 6 between Q4 2025 and Q1 2026.
- Reported value moved from $82,563,685 to $287,353.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 48 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 74065P101?
CUSIP 74065P101 identifies PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74065P101:
Significant Owners of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 16% | $44,259,932 | 12,935,071 | ORBIMED ADVISORS LLC | 21 Apr 2026 | |||
| BAKER BROS. ADVISORS LP | 16% | -33% | $35,227,431 | +$86,682 | 10,295,301 | +0.25% | Baker Bros. Advisors LP | 20 Apr 2026 |
| Vaddi Krishna | 13% | -4.6% | $19,562,376 | +$1,008,643 | 6,745,647 | +5.4% | Vaddi Krishna | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $22,157,579 | 6,477,309 | RA Capital Management, L.P. | 21 Apr 2026 | |||
| INCYTE CORP | 9.9% | $6,295,859 | 4,372,124 | INCYTE CORP | 03 Nov 2025 |
As of 31 Dec 2025, 48 institutional investors reported holding 28,472,272 shares of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD). This represents 44% of the company’s total 65,427,364 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 17% | 10,909,256 | 0% | 0.68% | $31,636,842 |
| BAKER BROS. ADVISORS LP | 15% | 10,123,824 | 0% | 0.17% | $29,359,090 |
| VANGUARD GROUP INC | 2.2% | 1,413,986 | +42% | 0% | $4,100,559 |
| Kynam Capital Management, LP | 1.2% | 788,867 | 0.15% | $2,287,714 | |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 788,695 | +418% | 0% | $2,287,216 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.2% | 755,956 | -14% | 0% | $2,193,000 |
| ACADIAN ASSET MANAGEMENT LLC | 0.82% | 535,703 | -0.9% | 0% | $1,551,000 |
| MORGAN STANLEY | 0.51% | 334,916 | +18% | 0% | $971,257 |
| MARSHALL WACE, LLP | 0.42% | 273,883 | 0% | $794,260 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.42% | 272,886 | +25% | 0% | $791,502 |
| RENAISSANCE TECHNOLOGIES LLC | 0.41% | 271,300 | -50% | 0% | $786,770 |
| BlackRock, Inc. | 0.41% | 266,280 | +0.49% | 0% | $772,212 |
| TWO SIGMA ADVISERS, LP | 0.36% | 237,300 | +6.6% | 0% | $688,170 |
| TD Asset Management Inc | 0.25% | 160,652 | 0% | 0% | $465,891 |
| MILLENNIUM MANAGEMENT LLC | 0.23% | 150,997 | -87% | 0% | $437,891 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.21% | 135,909 | 0% | $394,136 | |
| STATE STREET CORP | 0.19% | 127,292 | +30% | 0% | $369,147 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.19% | 122,752 | 0.07% | $355,981 | |
| GOLDMAN SACHS GROUP INC | 0.18% | 117,477 | +48% | 0% | $340,683 |
| JANE STREET GROUP, LLC | 0.17% | 111,040 | +219% | 0% | $322,016 |
| OMERS ADMINISTRATION Corp | 0.11% | 73,000 | 0% | $211,700 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.11% | 70,546 | +1.9% | 0% | $200,428 |
| Point72 Asset Management, L.P. | 0.09% | 59,168 | 0% | $171,587 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.08% | 53,500 | 0% | 0% | $155,150 |
| XTX Topco Ltd | 0.08% | 50,159 | +222% | 0% | $145,461 |
Institutional Holders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 83,662 | $287,353 | +$211,278 | $3.42 | 6 |
| 2025 Q4 | 28,472,272 | $82,563,685 | +$4,105,718 | $2.90 | 48 |
| 2025 Q3 | 27,161,835 | $39,111,943 | +$249,044 | $1.44 | 45 |
| 2025 Q2 | 27,187,955 | $21,995,839 | -$2,401,932 | $0.81 | 49 |
| 2025 Q1 | 30,289,302 | $23,267,043 | -$2,260,767 | $0.77 | 56 |
| 2024 Q4 | 32,136,788 | $40,964,573 | -$12,964,360 | $1.28 | 60 |
| 2024 Q3 | 35,754,682 | $74,021,916 | +$3,111,676 | $2.07 | 69 |
| 2024 Q2 | 33,917,161 | $129,220,239 | -$1,353,555 | $3.81 | 59 |
| 2024 Q1 | 34,197,005 | $162,095,049 | -$2,346,403 | $4.74 | 56 |
| 2023 Q4 | 34,725,223 | $148,268,893 | -$6,317,081 | $4.27 | 55 |
| 2023 Q3 | 36,614,209 | $113,138,241 | +$1,036,814 | $3.09 | 57 |
| 2023 Q2 | 36,273,689 | $163,232,997 | +$31,250,061 | $4.50 | 52 |
| 2023 Q1 | 31,510,272 | $179,609,477 | +$1,734,926 | $5.70 | 54 |
| 2022 Q4 | 31,178,634 | $188,300,136 | -$4,385,760 | $6.04 | 59 |
| 2022 Q3 | 31,821,580 | $210,332,653 | -$5,208,246 | $6.61 | 50 |
| 2022 Q2 | 32,736,159 | $170,877,689 | -$7,216,025 | $5.22 | 55 |
| 2022 Q1 | 34,109,145 | $235,382,986 | -$10,995,652 | $6.90 | 64 |
| 2021 Q4 | 35,151,511 | $437,636,391 | -$26,977,029 | $12.45 | 74 |
| 2021 Q3 | 35,967,344 | $1,123,981,157 | +$47,268,239 | $31.25 | 61 |
| 2021 Q2 | 34,458,535 | $986,644,054 | +$52,903,899 | $28.63 | 56 |
| 2021 Q1 | 32,543,650 | $1,410,113,760 | -$96,898,538 | $43.33 | 60 |
| 2020 Q4 | 34,651,491 | $2,474,382,581 | +$136,089,518 | $71.55 | 51 |
| 2020 Q3 | 33,322,061 | $999,836,330 | +$999,836,330 | $30.13 | 38 |